Pfizer offers EU concessions for Hospira deal OK; Glaxo teams up with Crick on HIV, cancer;

@FiercePharma: FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Emcure plant in Hinjwadi added to growing list of Indian facilities banned by FDA. More | Follow @EricPFierce

@CarlyHFierce: UPDATED with quote from $HZNP CEO Walbert: Depomed swallows poison pill to keep hostile Horizon at bay. Story | Follow @CarlyHFierce

> Pfizer ($PFE) offered concessions to win EU regulatory approval for its $15 billion takeover of U.S.-based Hospira ($HSP); details of Pfizer's proposal weren't disclosed. Report

> GlaxoSmithKline ($GSK) became the first drugmaker to hook up with England's new open innovation-focused Crick Institute, in a partnership focused on HIV, malaria and cancer. Release

> Greece banned exports of 25 drugs after finding abuses in re-exporting imported medicines, amid worries about shortages in the cash-strapped country. Report

> Bayer HealthCare won European approval for its imaging agent Gadovist (gadobutrol) for use in children under 2 years of age. Release

Medical Device News

@FierceMedDev: ICYMI: Xagenic reels in $15M for point-of-care testing system. FierceDiagnostics story | Follow @FierceMedDev\

@VarunSaxena2: ICYMI yesterday: India moving closer to implementing price controls on medical devices. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Otsuka, Lundbeck bag blockbuster FDA approval for long-acting antipsychotic Rexulti. Story | Follow @EmilyWFierce

> Valeant to buy contact lens maker Unilens for $28M. Story

> Gentag, Mayo Clinic and others form JV to develop cheap, painless smartphone-based diabetes tech. Article

Biotech News

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: BRIEF: Celgene backing Soon-Shiong's cancer biotech IPO, now dubbed NantKwest. Item | Follow @JohnCFierce

@DamianFierce: $SHPG's Ornskov has A+ dramaturgy. Was it "Can't Get You Outta My Head," @jonathanrockoff? More | Follow @DamianFierce

> Sarepta wants to 'own DMD' in rare disease race with BioMarin. Story

> GlaxoSmithKline joins the U.K.'s new Crick Institute for some open R&D. Article

> Biotech legend Lee Hood gambles $36M on a plan to revolutionize healthcare. Report

Pharma Manufacturing News

> Novartis' Sandoz puts India plant on chopping block. News

> Takeda recalls thousands of Contrave bottles even as it fights over canceled trial. Report

> WuXi selling chunk of SynTheAll to raise $80M for plant expansion. Story

> Catalent says it has resolved issues FDA noted at North Carolina site. Item

> Fresenius Kabi, Calea fined $844,600 for lapses tied to patient death. Article

Pharma Asia News

> Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. Article

> Fujifilm Chief Komori discusses R&D, earnings outlook, but not duodenoscopes. Story

> China's aim to halt malaria gets a thumbs up from WHO as global effort grows. Report

> Private placement of 6% in WuXi's SynTheAll unit raises $80M to fund manufacturing boost. More

Drug Delivery News

> Researcher says more work needed on use of nanocarriers in fight against stroke, heart disease. Report

> Eczema cream posts strong results in PhIII trial. Item

> Parisian MIT spinoff pulls in €2M to fund CRISPR delivery work. News

> Valeant to commercialize and manufacture EyeGate's eye drug delivery device. Story

> Neos files for $60M IPO with easy-to-swallow tablets for ADHD. Article

And Finally… The Obama administration has dragged its feet on FDA funding and implementation for a landmark food safety law passed in 2010, Politico reports. Story

Suggested Articles

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.

Sanofi has faced a probe into birth defects tied to seizure med Depakine for years. Now, the investigation is moving forward on manslaughter charges.

Pfizer launched a multichannel awareness campaign centered on a first-ever radio station dedicated solely to metastatic breast cancer.